Optimi Health Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Optimi Health şirketinin toplam hissedar öz sermayesi CA$10.7M ve toplam borcu CA$2.7M olup, bu da borç-öz sermaye oranını 24.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CA$15.1M ve CA$4.4M dir.

Anahtar bilgiler

24.9%

Borç/özkaynak oranı

CA$2.65m

Borç

Faiz karşılama oranı	n/a
Nakit	CA$245.84k
Eşitlik	CA$10.66m
Toplam yükümlülükler	CA$4.40m
Toplam varlıklar	CA$15.06m

Son finansal sağlık güncellemeleri

Recent updates

Here's Why Optimi Health (CSE:OPTI) Must Use Its Cash Wisely

Apr 07

Is Optimi Health (CSE:OPTI) In A Good Position To Deliver On Growth Plans?

Dec 07

We Think Optimi Health (CSE:OPTI) Can Afford To Drive Business Growth

May 25

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: OPTI 'nin kısa vadeli varlıkları ( CA$1.6M ) kısa vadeli yükümlülüklerini ( CA$1.7M ) kapsamıyor.

Uzun Vadeli Yükümlülükler: OPTI 'un kısa vadeli varlıkları ( CA$1.6M ) uzun vadeli yükümlülüklerini ( CA$2.7M ) karşılamamaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: OPTI 'nin net borç/öz sermaye oranı ( 22.6% ) tatmin edici olarak değerlendirilmektedir.

Borcun Azaltılması: OPTI şirketinin borç/öz sermaye oranının son 5 yılda azalıp azalmadığını belirlemek için yeterli veri yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: OPTI son raporlanan serbest nakit akışına göre 1 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: OPTI serbest nakit akışı tahminlerine göre 0 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

Optimi Health Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why Optimi Health (CSE:OPTI) Must Use Its Cash Wisely

Is Optimi Health (CSE:OPTI) In A Good Position To Deliver On Growth Plans?

We Think Optimi Health (CSE:OPTI) Can Afford To Drive Business Growth

Recent updates

Optimi Health Corp. Announces First PTSD Patients Treated with MDMA Capsules in Australia

Optimi Health Corp. Announces Chief Executive Officer Changes

Third quarter 2024 earnings released: CA$0.018 loss per share (vs CA$0.017 loss in 3Q 2023)

Optimi Health Corp. announced that it expects to receive CAD 5 million in funding

Co-Founder exercised options to buy CA$71k worth of stock.

Co-Founder exercised options to buy CA$68k worth of stock.

Second quarter 2024 earnings released: CA$0.016 loss per share (vs CA$0.014 loss in 2Q 2023)

Optimi Health Receives Certificate of Analysis for Mdma 40Mg and 60Mg Gmp Capsules

Optimi Health Corp. Receives Export Permit from Health Canada to Ship MDMA To Tel Aviv University's Institute for Psychedelic Research

Optimi Health Corp. Completes In-House Production of MDMA Active Pharmaceutical Ingredient

Optimi Health Corp. Receives Finished Product Test Results and Certificate of Analysis for GMP Natural Psilocybin Extract

First quarter 2024 earnings released: CA$0.014 loss per share (vs CA$0.015 loss in 1Q 2023)

New minor risk - Shareholder dilution

New major risk - Share price stability

Optimi Health Corp. announced that it expects to receive CAD 1.5 million in funding

Optimi Health Corp. announced that it expects to receive CAD 1.5 million in funding

Full year 2023 earnings released: CA$0.06 loss per share (vs CA$0.094 loss in FY 2022)

Optimi Health Corp., Annual General Meeting, Feb 22, 2024

Optimi Health Corp. Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing

Optimi Health Corp. Announces Executive Changes

Optimi Health Corp. Announces Encouraging Results from the MAPS Phase 3 MDMA-Assisted Therapy Clinical Trial

Third quarter 2023 earnings released: CA$0.017 loss per share (vs CA$0.017 loss in 3Q 2022)

Natural Health Grants Optimi Health Corp. Product Site License by Health Canada

Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists

Optimi Health Completes First Production of Novel MDMA Drug Candidate OPTI-MHCL

Optimi Health Corp. Announces Departs Michael Stier as Director

Less than half of directors are independent

Optimi Health Corp., Annual General Meeting, Jan 09, 2023

Optimi Health Corp. announced that it has received CAD 1.85 million in funding

Optimi Health, ATMA Journey Centers To Proceed With Phase I Natural Psilocybin and MDMA Clinical Trial Application to Health Canada

Co-Founder exercised options to buy CA$162k worth of stock.

Optimi Health Corp. Completes Larger Legal Natural Psilocybin Harvest

Optimi Health Corp. Appoints Justin Kirkland as Chief Science Officer

Optimi Health Corp. Appoints Jacob Safarik to its Board of Directors

Optimi Health Unveils Canada’s First Natural Therapeutic Psilocybin Product For Approved Patients

Key Executive exercised options to buy CA$596k worth of stock.

Optimi Health Corp. Requests Approval to Manufacture Mdma, Other Synthetic Psychedelics

Independent Director recently sold CA$50k worth of stock

Optimi Health Corp. Completes First Grow of Psilocybin Mushrooms

Less than half of directors are independent

Here's Why Optimi Health (CSE:OPTI) Must Use Its Cash Wisely

Optimi Health Corp. Launches E-Commerce Platform Featuring All-Natural Functional Mushroom Supplements

Key Executive recently bought CA$63k worth of stock

Optimi Labs Inc. Gets Dealer’s License by Health Canada

Optimi Health Corp., Annual General Meeting, Feb 24, 2022

Optimi Health Corp. Submits Natural Psilocybin Combined Drug Delivery and Extraction Formulations for Provisional Patent

Is Optimi Health (CSE:OPTI) In A Good Position To Deliver On Growth Plans?

Optimi Health and Numinus Wellness Inc. Completes Pre-Clinical Trial Application Meeting

Insider recently bought CA$70k worth of stock

Insider recently bought CA$70k worth of stock

We Think Optimi Health (CSE:OPTI) Can Afford To Drive Business Growth

Numinus Wellness and Optimi Health Submit All-Natural Psilocybin Extract to Health Canada for Pre-Clinical Trial Application

Insider recently bought CA$70k worth of stock

Optimi Health Corp. Receives Health Canada NPN Product Licenses in Preparation for Second Quarter of 2021 Sales Launch

Optimi Health Corp. Announces A Service Agreement with the Impact Clinical Trial Accelerator Program Housed Within Alberta’S Life Sciences Innovation Hub At the University of Calgary

Insider recently bought CA$53k worth of stock

Optimi Health and Numinus Wellness to Conduct Psychedelic Lab Research and Development

Insider recently bought CA$224k worth of stock

Optimi Health Corp. has completed an IPO in the amount of CAD 18 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin